This website requires JavaScript.
DOI: 10.1101/2023.05.24.542196

A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy

W. J.Dower A. I. Park A. V. Bakker ...+6 R. W. Barrett
摘要
Interleukin-7 (IL-7) is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia and infectious disease; and found to be relatively well-tolerated and biologically active. Here we describe novel IL-7R agonists that are unrelated in structure to IL-7, bind to the receptor subunits differently from IL-7, but closely emulate IL-7 biology. The small size, low structural complexity, and the natural amino acid composition of the pharmacologically active peptide MDK1472 allows facile incorporation into protein structures, such as the IgG2-Fc fusion MDK-703. This molecule possesses properties potentially better suited to therapeutic applications than native IL-7 or its derivatives. We compared these compounds with IL-7 for immune cell selectivity, induction of IL-7R signaling, receptor-mediated internalization, proliferation, and generation of immune cell phenotypes in human and non-human primate (NHP) peripheral blood cells in vitro; and found them to be similar in biological activity to IL-7. In cynomolgus macaques, MDK-703 exhibits a circulating half-life of 46 hr, and produces sustained T-cell expansion characteristic of IL-7 treatment. In the huCD34+-engrafted NSG mouse model of the human immune system, MDK-703 induces an immune cell profile very similar to that generated by IL-7-derived compounds; including the pronounced expansion of memory T-cells, particularly the population of stem-like memory T-cells (Tscm), which may be important for anti-tumor activities reported with IL-7 treatment. Clinical administration of IL-7 and modified variants has been reported to induce anti-drug antibodies (ADAs), including IL-7 neutralizing antibodies. The novel peptide agonist reported here scores very low in predicted immunogenicity, and because the peptide agonists lack sequence similarity with IL-7, the problematic immunogenic neutralization of endogenous cytokine should not occur.
展开全部
图表提取

暂无人提供速读十问回答

论文十问由沈向洋博士提出，鼓励大家带着这十个问题去阅读论文，用有用的信息构建认知模型。写出自己的十问回答，还有机会在当前页面展示哦。

Q1论文试图解决什么问题？
Q2这是否是一个新的问题？
Q3这篇文章要验证一个什么科学假设？
0
被引用
0
笔记
0
问答